A Case of EGFR‐mutant Squamous Cell Lung Cancer Treated With Necitumumab Combination Therapy

Background/Aim: There is insufficient evidence regarding the optimal treatment for squamous cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations, and a standard treatment strategy has not been established. Case Report: A 60‑year‑old woman was diagnosed with advanced EGFR‑mutant squamous cell lung cancer. She was treated with EGFR tyrosine kinase inhibitors and then received the combined therapy of cytotoxic agents plus immune checkpoint inhibitors as third‑line therapy. She was then treated with the fourth‑line combination therapy of cisplatin, gemcitabine, and necitumumab, which resulted in a progression‑free survival of 5.0 months and shrinkage of the liver metastatic lesion. Conclusion: The combination therapy of cisplatin, gemcitabine, and necitumumab was effective in treating pretreated EGFR‑mutant squamous cell lung cancer in this case. It is necessary to accumulate more evidence to determine the most effective treatment for advanced EGFR‑mutant squamous cell lung cancer.